Clinical trial
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
NCT00276263 · Herzog Hospital, Other · Withdrawn
Key facts
| NCT number | NCT00276263 |
|---|---|
| Title | Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia |
| Official title | Sarcosine (N-methylglycine) Trial for Individuals At Risk for Developing Schizophrenia and Related Disorders |
| Lead sponsor | Herzog Hospital, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenias, Psychoses, Psychotic Disorders, Schizophrenic Disorders |
| Intervention type | Drug |
| Interventions | Sarcosine (N-methylglycine) |
| Enrollment | 0 |
| Start date | Aug 1, 2006 |
| Completion | Jun 1, 2009 |
| First posted | Jan 13, 2006 |
| Last update posted | Jun 4, 2014 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: